MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2022 International Congress

    Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

    Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
  • 2022 International Congress

    A mouse model to test the cortical pathogenic theory of Parkinson’s disease

    M. Moreno-Gómez, D. Humanes-Valera, J. Pardo-Valencia, N. Mercado-García, B. Pro-Sánchez, A. Revuelto-González, T. Balzano, J. Blesa, A. Bortolozzi, J A. Obeso, G. Foffani (Móstoles, Spain)

    Objective: To develop a mouse model of chronic corticostriatal overactivity and increase expression of corticostriatal alpha-synuclein. Background: Parkinson’s disease typically has a focal motor onset1,…
  • 2022 International Congress

    The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation

    P. Kallunki, K. Willén, F. Sotty, L. Buur, K. Bjerregaard-Andersen, M. Lubas, D. Damlund, M. Harndahl, K. Fog (Valby, Denmark)

    Objective: Lu AF82422 is a human IgG1 monoclonal antibody that binds all known forms of alpha-synuclein (aSyn), including monomeric, aggregated and truncated. Data are presented…
  • 2022 International Congress

    Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes

    M. Banwinkler, V. Dzialas, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: The aim of this study was to test if markers of the brain-first Parkinson’s disease (PD) subtype are associated with a greater or more…
  • 2022 International Congress

    DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease

    A. Lavrinova, A. Zhuravlev, I. Miliukhina, E. Belykh, A. Tyurin, O. Berkovich, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

    Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells…
  • 2022 International Congress

    The study of clonidine growth hormone study amongst definite MSA, PD, PSP, and PAF patients to assess its feasibility as a future non-invasive biomarker

    S. Bhattacharjee, E. Vichayanrat, L. Watson, V. Iodice (London, United Kingdom)

    Objective: To analyze the sensitivity and specificity of the clonidine growth hormone (CGH) to distinguish probable multiple system atrophy (MSA) from pure autonomic failure (PAF),…
  • 2022 International Congress

    Clinical presentation of SNCA Duplication Parkinsonism in a Family Kindred

    K. Dent, M. Rochman, D. Kremens, J. Ratliff (Philadelphia, USA)

    Objective: To report phenotype variability in a family with SNCA duplication associated Parkinsonism. Background: Pathogenic variants in SNCA, the gene coding for α-synuclein, cause familial…
  • 2022 International Congress

    Myelination relevant plasma microRNA biomarkers identified via an innovative data analytic scheme for differential diagnosis of MSA, an Oligodendroglial Synucleinopathy

    CC. Lu, MC. Kuo, JW. Huang, Y-T. Tsai, H-H. Lin Wang, PJ. Kung, C-C. Wu, Y-Y. Hsueh, T. Ochiya, FKH. Phoa, S-P. Lin, R-M. Wu (Taipei, Taiwan)

    Objective: To establish an inclusive data analytic scheme to identify and characterize plasma microRNA biomarkers with pathophysiological significance for differentiating the atypical Parkinsonian, Multiple System…
  • 2022 International Congress

    IkT-148009 as a potential disease-modifying therapy in PD

    M. Werner, S. Karuppagounder, R. Rush, T. Kelly, T. Dawson, V. Dawson (Atlanta, USA)

    Objective: Modeling Parkinson’s disease in mice suggests c-Abl activation is required for PD initiation and progression, and therefore inhibition of c-Abl could be a strategy…
  • 2022 International Congress

    in vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson’s disease

    C. Shin, JY. Han, YP. Choi, SI. Kim, SH. Park, HK. Yang, HJ. Lee, SH. Kong, YS. Suh, HJ. Kim, B. Jeon (Sejong-si, Republic of Korea)

    Objective: To evaluate pathologic alpha-synuclein (AS) seeding activity with Real-time quaking-induced conversion (RT-QuIC) assay using formalin fixed paraffine-embedded (FFPE) tissue of GI tract in Parkinson's disease (PD)…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley